{"prompt": "['6', '0.4: Distribution of Clinical trial Protocols', 'Complete Version', 'Date', 'Writer', 'Receivers', 'Internal', 'Date released', 'review', 'Version 0.1 1', '28.10.2021', 'SL', 'BD, GP, BHH, HF, VL, EL', 'Yes', 'No', 'Version 0.2', '02.11.2021', 'SL', 'BD, GP, BHH, HF, VL, EL', 'Yes', 'No', 'Version 0.3', '15.11.2021', 'SL', 'BD, GP, BHH, HF, VL, EL, AS, HS', 'Yes', 'No', 'Final Version 1.0', '30.11.2021', 'SL', 'BD, GP, BHH, HF, VL, EL, AS, HS', 'No', '30.11.2021', 'Final Version 1.1', '10.12.2021', 'SL', 'BD, GP, BHH, HF, VL, EL, AS, HS', 'No', '30.11.2021', 'Final Version 1.2', '20.12.2021', 'SL', 'BD, GP, BHH, HF, VL, EL, AS, HS', 'No', '30.11.2021', 'Final Version 1.3', '19.01.2022', 'SL', 'BD, GP, BHH, HF, VL, EL, AS, HS', 'No', '30.11.2021', 'Final Version 1.4', '03.03.2022', 'SL', 'BD, GP, BHH, HF, VL, EL, AS, HS', 'No', '03.03.2022', 'Final Version 1.5', '22.03.2022', 'SL/BHH', 'BD, GP, HF, VL, EL, AS, HS', 'No', '03.03.2022', 'SL: Stig Larsen', 'BD: Bard Dalhoi', 'GP: Goran Petrovski', 'BHH: Bj\u00f8rn Helland Hansen', 'HF: Hans Fagertun', 'VL: Vivy Larsen', 'EL: Einar Lundberg', 'AS: Alexander Sverstad', 'HS: Henrik Skaret', '0.5: Participating Institutions', 'The study will be performed as a multicenter study at Oslo University Hospitals/Ullev\u00e4l and', 'Helgeland Hospital.', 'BulbiCam; Validity study:', 'V1_OTH/DR; AMD-I/2022:', 'Final Version 1.5 22nd March 2022']['7', 'Content', '0: Steering committee', '1', '0.1: Signature Sheet', '3', '0.2: Contact names and addresses', '4', '0.3: List of Abbreviations', '5', '0.4: Distribution of Clinical trial Protocols', '6', '0.5: Participating Institutions', '6', 'I: Protocol Synopsis', '10', '1.1: Title', '10', '1.2: Protocol number', '10', '1.3: Aim', '10', '1.4: Study population', '10', '1.5: Trial equipment', '10', '1.6: Design', '10', '1.7: Variables', '11', '1.7.1 Main Variables', '11', '1.7.2 Supporting Variables', '12', '1.8: Study procedure', '12', '1.9: Sample size', '13', '1.10: Time schedule', '13', '1.11: Flow chart', '13', 'II: Introduction', '14', '2.1: Background', '14', '2.1.1:Diabetic Retinopathy (DR)', '14', '2.1.2: Age-related macular degeneration (AMD)', '14', '2.2: BulbiCam', '15', '2.3: Standard Method', '16', '2.4: Objective', '16', 'III: Population and sampling', '18', '3.1: Reference population', '18', '3.2: Study populations', '18', '3.2.1: Inclusion criteria; study population 1 (DR)', '18', '3.2.2: Exclusion criteria; study population 1 (DR)', '18', '3.2.3: Inclusion criteria; study population 2 (AMD)', '18', '3.2.4: Exclusion criteria; study population 2 (AMD)', '18', '3.2.5: Inclusion criteria; study population 3 (HC)', '19', '3.2.6: Exclusion criteria; study population 3 (HC)', '19', '3.3: Recruitment of patients', '19', '3.4: Benefit and risk assessment', '19', 'IV: Design', '20', '4.1: Study design', '20', '4.2: Stratification', '20', '4.3: Identification of patients', '21', 'V: Evaluation', '22', '5.1: Main variables', '22', '5.1.1: BulbiCam investigation', '22', '5.2: Secondary variables', '23', '5.2.1: Quality-of- Life questionnaires30', '23', '5.2.2: Common Terminology Criteria for Adverse Events version 4.0', '25', '5.3: Patient factors', '27', 'VI: Study procedure', '29', '6.1: Trial equipment and clinical procedure', '29', 'BulbiCam; Validity study:', 'V1_OTH/DR; AMD-I/2022:', 'Final Version 1.5 22nd March 2022']\n\n###\n\n", "completion": "END"}